A-966492 is a potent PARP inhibitor, which displayed excellent potency against the PARP-1 enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay. In addition, A-966492 is orally bioavailable across multiple species, crosses the blood-brain barrier, and appears to distribute into tumor tissue. It also demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide and in an MX-1 breast cancer xenograft model both as a single agent and in combination with carboplatin.
Related Products:
Afatinib dimaleate; Neratinib; Bosutinib; Bosutinib Intermediates; Bosutinib Monohydrate; Saracatinib; Dasatinib; NVP-BHG712; PP1; PP2; G007-LK; SU6656; Tirbanibulin; TPX-0005; Afatinib